LUX-head and neck 2: Randomized, double-blind, placebo-controlled, phase III trial of afatinib as adjuvant therapy after chemoradiation (CRT) in primary unresected, high/intermediate-risk, squamous cell cancer of the head and neck (HNSCC) patients (pts).
Barbara Burtness(Yale University), Ezra E.W. Cohen(Moores Cancer Center), Irina A. Vasilevskaya, Jan B. Vermorken(University of Antwerp), Makoto Tahara(National Cancer Center Hospital East), Luciano de Souza Viana(Hospital de Câncer de Barretos), Chaitali Nangia(University of California, Irvine Medical Center), Amanda Psyrri(National and Kapodistrian University of Athens), José Dinis(Instituto Português de Oncologia Francisco Gentil), И. С. Романов(Russian Cancer Research Center NN Blokhin), Kevin J. Harrington(Royal Marsden NHS Foundation Trust), Jean Bourhis(University of Lausanne), Robert I. Haddad(Georgetown University), Bushi Wang(Boehringer Ingelheim (United States)), J. G. M. Segalla(Apple (Israel)), E. Ehrnrooth(Boehringer Ingelheim (Germany)), Manuel Chaves-Conde(Hospital Universitario Virgen del Rocío), Jose M. Pérez(Hospital Clínico Universitario Virgen de la Victoria), Tomoya Yokota(Target (United States)), Neil Gibson(Boehringer Ingelheim (Germany))
Cited by 13
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Defining risk levels in locally advanced head and neck cancers: A comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501)
|Head & Neck|2005|1.8k
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
|New England Journal of Medicine|2007|1.7k
Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2020|1.4k